Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 13 | 2018 | 466 | 2.100 |
Why?
|
| Liver Cirrhosis | 4 | 2017 | 37 | 1.090 |
Why?
|
| Dendritic Cells | 4 | 2014 | 33 | 0.780 |
Why?
|
| Hepatitis C | 3 | 2017 | 32 | 0.750 |
Why?
|
| Lymphocyte Activation | 5 | 2014 | 82 | 0.690 |
Why?
|
| Coinfection | 2 | 2017 | 20 | 0.660 |
Why?
|
| Hepatitis C, Chronic | 2 | 2016 | 21 | 0.540 |
Why?
|
| Microbiota | 1 | 2018 | 95 | 0.530 |
Why?
|
| Viremia | 1 | 2016 | 8 | 0.530 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2016 | 1 | 0.520 |
Why?
|
| Hepatocytes | 1 | 2016 | 11 | 0.510 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 53 | 0.500 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 158 | 0.490 |
Why?
|
| T-Lymphocytes | 3 | 2010 | 96 | 0.480 |
Why?
|
| Aging | 2 | 2018 | 1544 | 0.470 |
Why?
|
| Bacterial Translocation | 1 | 2013 | 20 | 0.420 |
Why?
|
| Interferon-alpha | 2 | 2009 | 26 | 0.400 |
Why?
|
| Anti-Retroviral Agents | 2 | 2014 | 17 | 0.390 |
Why?
|
| HIV-1 | 2 | 2011 | 221 | 0.360 |
Why?
|
| Immune System | 1 | 2010 | 15 | 0.340 |
Why?
|
| Chloroquine | 1 | 2009 | 7 | 0.330 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 64 | 0.320 |
Why?
|
| Receptors, Chemokine | 2 | 2007 | 9 | 0.300 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2017 | 53 | 0.290 |
Why?
|
| Cells, Cultured | 3 | 2016 | 520 | 0.250 |
Why?
|
| Hepacivirus | 2 | 2016 | 15 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2017 | 189 | 0.240 |
Why?
|
| Interleukins | 2 | 2015 | 23 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2014 | 61 | 0.230 |
Why?
|
| Caspase 3 | 2 | 2016 | 20 | 0.220 |
Why?
|
| Plasma | 2 | 2014 | 16 | 0.220 |
Why?
|
| Flaviviridae Infections | 2 | 2013 | 2 | 0.210 |
Why?
|
| GB virus C | 2 | 2013 | 2 | 0.210 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2013 | 3 | 0.210 |
Why?
|
| Disease Progression | 2 | 2017 | 673 | 0.210 |
Why?
|
| Humans | 17 | 2018 | 27074 | 0.200 |
Why?
|
| Viral Load | 3 | 2014 | 69 | 0.200 |
Why?
|
| Adult | 11 | 2017 | 7831 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2012 | 107 | 0.190 |
Why?
|
| Cytokines | 2 | 2013 | 222 | 0.180 |
Why?
|
| Middle Aged | 7 | 2017 | 8923 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2016 | 111 | 0.170 |
Why?
|
| Female | 12 | 2017 | 15213 | 0.160 |
Why?
|
| HIV | 2 | 2016 | 39 | 0.160 |
Why?
|
| Antigens, CD | 2 | 2009 | 50 | 0.150 |
Why?
|
| Biological Therapy | 1 | 2018 | 2 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2017 | 10 | 0.150 |
Why?
|
| Dysbiosis | 1 | 2018 | 45 | 0.140 |
Why?
|
| Interleukin-2 | 1 | 2016 | 22 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 4 | 0.130 |
Why?
|
| Microscopy, Atomic Force | 1 | 2016 | 5 | 0.130 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 3 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 2016 | 34 | 0.130 |
Why?
|
| Herpes Labialis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Herpes Genitalis | 1 | 2015 | 6 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 891 | 0.120 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2015 | 2 | 0.120 |
Why?
|
| Surface-Active Agents | 1 | 2015 | 5 | 0.120 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 14 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 199 | 0.120 |
Why?
|
| Peripheral Nerves | 1 | 2015 | 17 | 0.120 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 94 | 0.120 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 4 | 0.120 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 15 | 0.120 |
Why?
|
| HIV Long-Term Survivors | 2 | 2014 | 5 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 92 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 420 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 346 | 0.110 |
Why?
|
| Peptides | 1 | 2015 | 102 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2014 | 45 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 20 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 30 | 0.110 |
Why?
|
| Vagina | 1 | 2014 | 35 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 35 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 37 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1368 | 0.110 |
Why?
|
| Biomarkers | 2 | 2017 | 562 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 56 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 61 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 6 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 381 | 0.090 |
Why?
|
| Animals | 2 | 2016 | 3642 | 0.090 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 5 | 0.090 |
Why?
|
| Receptors, CCR7 | 2 | 2007 | 6 | 0.090 |
Why?
|
| HIV Antigens | 1 | 2010 | 11 | 0.080 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2009 | 4 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 11 | 0.080 |
Why?
|
| Imidazoles | 2 | 2007 | 59 | 0.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2009 | 18 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 41 | 0.080 |
Why?
|
| Virus Replication | 1 | 2010 | 51 | 0.080 |
Why?
|
| Inflammation | 1 | 2011 | 272 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2009 | 118 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 66 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2015 | 1778 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2014 | 102 | 0.080 |
Why?
|
| Blood Cell Count | 1 | 2007 | 12 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2007 | 14 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 68 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 158 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2007 | 170 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 17 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 53 | 0.060 |
Why?
|
| Child | 1 | 2007 | 1295 | 0.050 |
Why?
|
| Adolescent | 1 | 2007 | 2172 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2017 | 74 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2013 | 1890 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 145 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 587 | 0.030 |
Why?
|
| Schwann Cells | 1 | 2015 | 2 | 0.030 |
Why?
|
| Gels | 1 | 2015 | 14 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 100 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 130 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2014 | 11 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2015 | 25 | 0.030 |
Why?
|
| Collagen | 1 | 2015 | 86 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 121 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 80 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 310 | 0.030 |
Why?
|
| Materials Testing | 1 | 2015 | 129 | 0.030 |
Why?
|
| Vaginal Douching | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 175 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 247 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 2 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2013 | 14 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 18 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2013 | 11 | 0.030 |
Why?
|
| Rats | 1 | 2015 | 664 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 474 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2012 | 31 | 0.030 |
Why?
|
| Alleles | 1 | 2013 | 216 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 420 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 415 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2011 | 7 | 0.020 |
Why?
|
| United States | 1 | 2017 | 2035 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 37 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 2302 | 0.020 |
Why?
|
| Poly I-C | 1 | 2006 | 6 | 0.020 |
Why?
|
| Ligands | 1 | 2006 | 39 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2006 | 81 | 0.020 |
Why?
|
| Male | 1 | 2012 | 14772 | 0.010 |
Why?
|